Literature DB >> 11575264

Apical hypertrophic cardiomyopathy mimics acute coronary syndrome.

T Sayin, T Koçum, C Kervancioglu.   

Abstract

We present a case who was initially thought to have an acute coronary syndrome but who was later diagnosed to have an apical hypertrophic cardiomyopathy. Interestingly, the diagnosis could be established with left heart catheterization, not echocardiography.

Entities:  

Mesh：

Year:  2001        PMID： 11575264     DOI： 10.1016/s0167-5273(01)00442-9

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


  5 in total

Review 1.  Nuclear cardiac imaging in hypertrophic cardiomyopathy.

Authors:  Jamshid Shirani; Vasken Dilsizian
Journal:  J Nucl Cardiol       Date:  2011-02       Impact factor: 5.952

2.  Resting "Solar Polar" map pattern and reduced apical flow reserve: characteristics of apical hypertrophic cardiomyopathy on SPECT myocardial perfusion imaging.

Authors:  R Parker Ward; Hemlata K Pokharna; Roberto M Lang; Kim A Williams
Journal:  J Nucl Cardiol       Date:  2003 Sep-Oct       Impact factor: 5.952

3.  Myocardial perfusion SPECT in the diagnosis of apical hypertrophic cardiomyopathy.

Authors:  Tomás F Cianciulli; María C Saccheri; Osvaldo H Masoli; Marcela F Redruello; Jorge A Lax; Luis A Morita; Juan A Gagliardi; Adriana N Dorelle; Horacio A Prezioso; Luis A Vidal
Journal:  J Nucl Cardiol       Date:  2009-01-09       Impact factor: 5.952

4.  Usefulness of ECG to differentiate apical hypertrophic cardiomyopathy from non-ST elevation acute coronary syndrome.

Authors:  Yirao Tao; Jing Xu; Samira Yerima Bako; Xiaobo Yao; Donghui Yang
Journal:  BMC Cardiovasc Disord       Date:  2020-06-23       Impact factor: 2.298

5.  Acute coronary syndrome with non-obstructive coronary arteries (ACS-NOCA) in patients with hypertrophic cardiomyopathy.

Authors:  Sarinya Puwanant; Angkawipa Trongtorsak; Chaisiri Wanlapakorn; Nattakorn Songsirisuk; Aekarach Ariyachaipanich; Smonporn Boonyaratavej
Journal:  BMC Cardiovasc Disord       Date:  2021-11-19       Impact factor: 2.298
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.